Sparfloxacin monograph

The following connectors are some of the products that may be suitable for deck retrofit. Selection of products based upon performance and or suitability for a specific application should be made by a qualified professional. Simpson recommends that product choice be approved by the local building department before work begins.
Coding for blood products and services in the hospital inpatient setting inpatient hospital billing for blood and blood services requires several types of codes: icd-9-cm diagnosis codes, icd-9-cm procedure codes, medicare revenue codes to describe the category of service performed, and medicare value codes to assign amounts or values for blood not applicable when the provider does not charge for the blood itself, but only for blood processing.
FIG. 1. Growth of L. pneumophila serogroup 1, strain F889 day of incubation after initiation of infection. Antimicrobial agents were added to infected macrophages 1 day after infection and after wells were washed to remove extracellular bacteria. Two days later day 3 ; , after supernatant sampling, wells were washed to remove antimicrobial agents. The two vertical arrows designate the times of antimicrobial agent addition day 1 ; and removal day 3 ; . Viable counts of L. pneumophila were determined from the culture supernatant on the specified days, except on day 1, when the absolute concentration of intracellular bacteria was determined by sonication and culture of replicate wells. All points represent the mean of triplicate wells counted in duplicate. Bacterial counts lower than 50 CFU ml could not be detected, which is designated by a solid horizontal line. Control wells contained no antimicrobial agents, CIPRO .25 and CIPRO 1 contained 0.25 and 1.0 , ug of ciprofloxacin per ml, respectively, and SPA .25 and SPA 1 contained 0.25 and 1.0 , ug of sparfloxacin per ml, respectively.

Same period in the same ward but in different rooms who had not received FQ for at least 5 months, and iii ; nonhospitalized healthy controls not exposed to FQs. VGS were identified by using the Rapid ID32 Strep system bioMerieux, Marcy l'Etoile, France ; and, when necessary, by nucleotide sequencing of an internal fragment of sodA 19 ; . Oropharyngeal samples were suspended in distilled sterile water and spread on Columbia agar Difco, Paris, France ; supplemented with 4% horse blood and colimycin 10 g ml ; with or without ciprofloxacin 3 g ml ; Plates were incubated at 37C in the presence of 5% CO2 for 48 h. To avoid false-positive results due to the possible selection of spontaneous mutants, samples which yielded less than 20 colonies on the FQ-containing plates were not considered. Inocula of 5 103 to 5 104 CFU were spotted on MuellerHinton agar plates supplemented with 4% horse blood and containing one of the following antibiotics: sparfloxacin Rhone Poulenc Rohrer, Vitry-sur-Seine, France ; , ciprofloxacin Bayer Pharma, Puteaux, France ; , and norfloxacin Merck Sharp & Dohme-Chibret, Paris, France ; . MICs were read after 18 h. To detect the presence of an efflux phenotype, MICs were also determined in the presence of reserpine 10 g ml ; 3, DNA extraction and PCR experiments were done as previously described 1, 11 ; . Oligonucleotides PNC6 and PNC7 11 ; and gyrB376 and gyrB512 13 ; were used for the amplification of the QRDRs of gyrA and gyrB, respectively. Oligonucleotides PNC10 and PNC11 11 ; were used to amplify the QRDR of parC, except for five strains of S. mitis, for which PARC56 5 -GACAAGAGCTACCGTAAGTC-3 ; and PARC117 5 GACAAACGIGCCTCIGTATAACG-3 ; were used. Amplification of the corresponding parE region was done either with oligonucleotides PNC15 and PNC16 11 ; or with parE398 and parE483 8 ; . Direct sequencing of DNA fragments, with the oligonucleotides used for amplification, was performed with the dRhodamine BigDye Terminator sequencing kit PerkinElmer, Applied Biosystems Division ; . The nucleotide sequences were analyzed with Perkin-Elmer software Sequence Analysis and Sequence Navigator ; . Multiple alignments of sequences were carried out using the CLUSTAL X program. Transformation experiments were carried out as previously described 10, 11 ; using DNA from viridans streptococci and the wild-type S. pneumoniae strain R6 as a recipient 15.

On Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. Maxwell, A. 1992. The molecular basis of quinolone action. J. Antimicrob. Chemother. 30: 409416. Mitsuyama, J.-I., Y. Itoh, M. Takahat, S. Okamoto, and T. Yasuda. 1992. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium. Antimicrob. Agents Chemother. 36: 20302036. Noumi, T., N. Nishida, S. Minami, Y. Watanabe, and T. Yashuda. 1990. Intracellular activity of tosufloxacin T-3262 ; against Salmonella enteritidis and ability to penetrate into tissue culture cells of human origin. Antimicrob. Agents Chemother. 34: 949953. Oksenhendler, E., J. Cadranel, C. Sarfati, C. Katlama, A. Datry, C. Marche, M. Wolf, P. Roux, F. Derouin, and J. P. Clauvel. 1990. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome. Am. J. Med. 88: 18N21N. Pomeroy, C., and G. A. Filice. 1992. Pulmonary toxoplasmosis: a review. Clin. Infect. Dis. 14: 863870. Sahai, J., T. Heimberger, K. Collins, L. Kaplowitz, and R. Polk. 1988. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am. J. Med. 84: 791792. Letter. ; Sutcliffe, J. A., T. D. Gootz, and J. F. Barrett. 1989. Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob. Agents Chemother. 33: 20272033. Teng, R., L. C. Dogolo, S. A. Willavize, and J. Vincent. 1995. Effect of age and gender on the pharmacokinetics of CP-99, 219, a new quinolone antibiotic, in healthy volunteers, p. 154, abstr. F238. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin CP-99, 219 ; , a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36: 385394. Torroba, A. L., D. J. Hermida, B. C. Ezpeleta, and Z. E. Munoz. 1988. Metahemoglobinemia secundaria al tratamiento de infecciones oportunistas en pacientes con SIDA. Rev. Clin. Esp. 182: 289290. Letter. ; Van Der Pol, B., and R. B. Jones. 1995. In vitro activity of CP99, 219 against Chlamydia trachomatis, p. 154, abstr. F237. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. Visalli, M., M. Jacobs, and P. Appelbaum. 1995. Antipneumococcal activity of CP 99, 219, ciprofloxacin, lomefloxacin, clinafloxacin, sparfloxacin and cefuroxime by time-kill testing, p. 154, abstr. F233. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. Wise, R., D. Mortiboy, J. Child, and J. M. Andrews. 1996. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin CP-99, 219 ; . Antimicrob. Agents Chemother. 40: 4749. Wong, S.-Y., D. M. Israelski, and J. S. Remington. 1994. AIDS associated toxoplasmosis, p. 460493. In M. A. Sande and P. Volberding ed. ; , The medical management of AIDS, 4th ed. The W. B. Saunders Co., Philadelphia. Wong, S.-Y., and J. S. Remington. 1994. Toxoplasmosis in the setting of AIDS, p. 223257. In S. Broder, T. C. Merigan, and D. Bolognesi ed. ; , Textbook of AIDS medicine. The Williams & Wilkins Co., Baltimore. Zimmer, C., K. Storl, and J. Storl. 1990. Microbial DNA topoisomerases and their inhibition by antibiotics. J. Basic Microbiol. 30: 209224 and spectinomycin.